Steven G Potkin1, Tatsuya Kimura2, John Guarino3. 1. Department of Psychiatry and Human Behavior, University of California-Irvine, 5251 California Avenue, Ste 240, Irvine, CA 92617, USA. 2. Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd, Tokyo, Japan. 3. Global Development Administration, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA.
Abstract
OBJECTIVE: The objective of this study was to evaluate the short-term efficacy and safety of the atypical antipsychotic agent lurasidone in the treatment of schizophrenia. METHODS: In this phase II, randomized, double-blind, placebo-controlled study, hospitalized adult patients diagnosed with schizophrenia and experiencing an acute exacerbation of psychotic symptoms were randomly assigned to 6 weeks of fixed-dose lurasidone 20 mg/day (n = 71), lurasidone 40 mg/day (n = 67), lurasidone 80 mg/day (n = 71), haloperidol 10 mg/day (n = 72, included to test for assay sensitivity), or placebo (n = 72). Efficacy was assessed using the brief psychiatric rating scale, positive and negative syndrome scale, and clinical global impression-severity. Safety assessments included incidence of adverse events and clinical laboratory measures. RESULTS:Numerical improvement was observed from baseline to week 6 (last observation carried forward) on all efficacy measures in all treatment groups; however, no statistically significant differences were noted between any lurasidone group and placebo, or between haloperidol and placebo. The most common adverse events in lurasidone-treated patients, with an incidence of at least 10% (dose groups combined) and greater than placebo, were sedation (15.3%), dyspepsia (13.4%), nausea (13.4%), akathisia (12.4%), and vomiting (10.5%); for haloperidol, the most common adverse events (incidence ⩾ 10% and greater than placebo) were extrapyramidal disorder (20.8%), sedation (19.4%), akathisia (19.4%), dystonia (15.3%), insomnia (13.9%), and somnolence (12.5%). Lurasidone was associated with minimal changes in weight, metabolic parameters, and prolactin levels. CONCLUSIONS: None of the lurasidone groups separated from placebo in this clinical study of patients with acute schizophrenia. In addition, haloperidol, which was included for assay sensitivity, did not separate from placebo, resulting in a failed study. Possible reasons for the lack of assay sensitivity in this study include the use of multiple active treatment arms and the relatively large placebo response. Consistent with other studies, lurasidone was generally safe and well tolerated, with minimal effects on weight or metabolic parameters.
RCT Entities:
OBJECTIVE: The objective of this study was to evaluate the short-term efficacy and safety of the atypical antipsychotic agent lurasidone in the treatment of schizophrenia. METHODS: In this phase II, randomized, double-blind, placebo-controlled study, hospitalized adult patients diagnosed with schizophrenia and experiencing an acute exacerbation of psychotic symptoms were randomly assigned to 6 weeks of fixed-dose lurasidone 20 mg/day (n = 71), lurasidone 40 mg/day (n = 67), lurasidone 80 mg/day (n = 71), haloperidol 10 mg/day (n = 72, included to test for assay sensitivity), or placebo (n = 72). Efficacy was assessed using the brief psychiatric rating scale, positive and negative syndrome scale, and clinical global impression-severity. Safety assessments included incidence of adverse events and clinical laboratory measures. RESULTS: Numerical improvement was observed from baseline to week 6 (last observation carried forward) on all efficacy measures in all treatment groups; however, no statistically significant differences were noted between any lurasidone group and placebo, or between haloperidol and placebo. The most common adverse events in lurasidone-treated patients, with an incidence of at least 10% (dose groups combined) and greater than placebo, were sedation (15.3%), dyspepsia (13.4%), nausea (13.4%), akathisia (12.4%), and vomiting (10.5%); for haloperidol, the most common adverse events (incidence ⩾ 10% and greater than placebo) were extrapyramidal disorder (20.8%), sedation (19.4%), akathisia (19.4%), dystonia (15.3%), insomnia (13.9%), and somnolence (12.5%). Lurasidone was associated with minimal changes in weight, metabolic parameters, and prolactin levels. CONCLUSIONS: None of the lurasidone groups separated from placebo in this clinical study of patients with acute schizophrenia. In addition, haloperidol, which was included for assay sensitivity, did not separate from placebo, resulting in a failed study. Possible reasons for the lack of assay sensitivity in this study include the use of multiple active treatment arms and the relatively large placebo response. Consistent with other studies, lurasidone was generally safe and well tolerated, with minimal effects on weight or metabolic parameters.
Authors: Antony Loebel; Josephine Cucchiaro; Jane Xu; Kaushik Sarma; Andrei Pikalov; John M Kane Journal: Schizophr Res Date: 2013-04-11 Impact factor: 4.939
Authors: Antony Loebel; Josephine Cucchiaro; Kaushik Sarma; Lei Xu; Chuanchieh Hsu; Amir H Kalali; Andrei Pikalov; Steven G Potkin Journal: Schizophr Res Date: 2013-02-13 Impact factor: 4.939
Authors: Henry A Nasrallah; Robert Silva; Debra Phillips; Josephine Cucchiaro; Jay Hsu; Jane Xu; Antony Loebel Journal: J Psychiatr Res Date: 2013-02-17 Impact factor: 4.791
Authors: Leslie Citrome; Peter J Weiden; Joseph P McEvoy; Christoph U Correll; Josephine Cucchiaro; Jay Hsu; Antony Loebel Journal: CNS Spectr Date: 2013-12-16 Impact factor: 3.790
Authors: Maria S Neumeier; Stephanie Homan; Stefan Vetter; Erich Seifritz; John M Kane; Maximilian Huhn; Stefan Leucht; Philipp Homan Journal: Schizophr Bull Date: 2021-10-21 Impact factor: 7.348